Medtronic Alumni Take Up SetPoint Regulatory Leadership Roles
SetPoint Medical appoints senior regulatory execs as it advances neuromodulation clinical trials.
You may also be interested in...
As rheumatoid arthritis treatment improves in the biologics era, patients need fewer joint replacements. Instead, they now require more closely monitored, agile care, in the face of a growing shortage of qualified rheumatologists. These demands help propel digital health applications, bioelectronic devices and novel imaging modalities into the medtech spotlight.
Pharmaceuticals group GlaxoSmithKline has launched a new $50m venture capital fund dedicated to investing in “bioelectronic medicines”, an emerging generation of neuromodulation technologies designed to treat diseases ranging from autoimmune and inflammatory conditions to respiratory disorders.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.